The data come from Merck’s Keynote-024 trial, which nabbed Keytruda a solo nod in first-line NSCLC just a couple weeks after the New Jersey drugmaker presented results at ESMO’s 2016 confab. At the ESMO 2022 meeting, Merck also provided a five-year update from the KEYNOTE-407 trial, which has been supporting Keytruda’s use alongside chemo in newly diagnosed squamous NSCLC. The company undertakes no obligation to publicly update. Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study. with a median PFS of 9.0 months versus 4.9 months and a five-year PFS rate of 7.5 versus 0.6. RELATED: Merck's Keytruda wins coveted first-line lung cancer nod, cementing rise 'from laggard to leader' Background Primary analysis of KEYNOTE-042 (NCT022208941), a global, randomized, phase 3 trial, showed that pembrolizumab significantly improved OS versus platinum-based chemotherapy in patients with locally advanced or metastatic nonsmall-cell lung cancer (NSCLC) without sensitizing EGFR/ALK alterations and with PD-L1 tumor proportion score (TPS) 50, 20, and 1 with fewer. Data presented from the 4-year follow-up to the phase 3 KEYNOTE-042 trial display continuous survival benefit of pembrolizumab vs chemotherapy. “If you look at the percentage of patients who actually finished two years of therapy with Keytruda … 80% of those patients were alive at five years, and about half of those patients had not required any subsequent therapies,” he said. “I think it’s tremendously encouraging for patients that are facing a lung cancer diagnosis to be able to think about living for five years or longer from the time they’re diagnosed,” Scot Ebbinghaus, Merck VP of clinical research, said.īefore Keytruda hit the scene, the five-year survival mark in this patient group “was in the ballpark of 5%,” he noted.Īnd there was another feature of the data set Ebbinghaus pointed to as “remarkable.” The five-year survival rate for patients suffering from highly advanced. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases. year of production of your Honda Accord and location This J Pipe for. The two main types of lung cancer are non-small cell and small cell. 5 different trusted brands of Exhaust Pipe & Flange Gasket products. Keytruda monotherapy also clocked a median response lasting 29.1 months, nearly five times longer than chemo’s 6.3 months, according results presented Monday at the European Society for Medical Oncology’s virtual annual meeting. Each year, more people die of lung cancer than die of colon, breast and prostate cancers combined.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |